Lung Cancer

AFT-57

Randomized phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoimmunotherapy for unresectable stage III NSCLC

---

URCC 19185

Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

---

EAY191-A3 **Cohort 3 (Pancreatic Cancer) Temp. Suspended as of 4/15/24**

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

---

NRG-LU008

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

---

EAY191-E4 **Accrual to EAY191-E4 is Temporarily Suspended effective January 12, 2024**

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors

---

URCC 22063

Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia (LOTUS-CC)

---

AFT-63

DNA Evaluation of Fragments for Early Interception – Lung Cancer Training Study (DELFI-L101 Study)

---

EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice

---

SWOG S1900G

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

---

A021901 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

---